From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
FIN56 is a specific inducer of ferroptosis. FIN56 induces ferroptosis by inducing degradation of GPX4. FIN56 also binds to and activates squalene synthase .
OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K + channels and has Ca 2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .
OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure .
Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation .
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
3,5-Dinitrocatechol (OR-486) is a potent catechol-O-methyltransferase inhibitor, with an IC50 of 12 nM. 3,5-Dinitrocatechol can be used in the preparation of the molybdenum (VI)- 3,5-Dinitrocatechol complex .
OR1A1 Human Pre-designed siRNA Set A contains three designed siRNAs for OR1A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR1A2 Human Pre-designed siRNA Set A contains three designed siRNAs for OR1A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR2AT4 Human Pre-designed siRNA Set A contains three designed siRNAs for OR2AT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR2H1 Human Pre-designed siRNA Set A contains three designed siRNAs for OR2H1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR2M7 Human Pre-designed siRNA Set A contains three designed siRNAs for OR2M7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR4F17 Human Pre-designed siRNA Set A contains three designed siRNAs for OR4F17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR4F5 Human Pre-designed siRNA Set A contains three designed siRNAs for OR4F5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR51E1 Human Pre-designed siRNA Set A contains three designed siRNAs for OR51E1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR51E2 Human Pre-designed siRNA Set A contains three designed siRNAs for OR51E2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR5B21 Human Pre-designed siRNA Set A contains three designed siRNAs for OR5B21 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR6A2 Human Pre-designed siRNA Set A contains three designed siRNAs for OR6A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
OR7D4 Human Pre-designed siRNA Set A contains three designed siRNAs for OR7D4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
DOG-IM4 can be used to synthesize nanoparticles to deliver antigen-encoding nucleic acids. It could be used to try to target autoimmune diseases, rare blood or metabolic diseases, allergies, cancer or infectious diseases .
PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research .
IRE1α kinase-IN-8, a benzoheterocyclecarboxaldehyde derivative, is a potent IRE-1α inhibitor. IRE1α kinase-IN-8 can be used for research in diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) .
MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH) .
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
Nocistatin, a neuropeptide, is an endogenous ligand for the orphan opioid receptor-like receptor. Nocistatin is also a functional antagonist of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a Gi/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
BC15 aptamer sodium is an ssDNA aptamer targeting the intracellular protein hnRNP A1, which is highly expressed in cancerous liver tissue. BC15 aptamer sodium specifically recognizes breast cancer cells and can be used to detect cancer cells in other pathological types of breast cancer tissue .
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
Nocistatin, a neuropeptide, is an endogenous ligand for the orphan opioid receptor-like receptor. Nocistatin is also a functional antagonist of neuropeptide nociceptin or orphanin FQ (Noc/OFQ). Nocistatin inhibits 5-HT release via a Gi/o proteinmediated pathway. Nocistatin blocks Nociceptin (Nociceptin)-induced allodynia and hyperalgesia .
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
The OPRD1 protein is a G protein-coupled receptor for enkephalins and opioids that undergoes ligand-induced conformational changes to activate signaling through G proteins and inhibit adenylate cyclase. Additionally, it reduces neurotransmitter release by affecting ionic currents. OPRD1 Protein, Human (Cell-Free, His) is the recombinant human-derived OPRD1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of OPRD1 Protein, Human (Cell-Free, His) is 372 a.a., with molecular weight of 41.9 kDa.
OR13A1 operates as an odorant receptor. OR13A1 Protein, Human (Cell-Free, His) is the recombinant human-derived OR13A1 protein, expressed by E. coli Cell-free, with N-10*His labeled tag. The total length of OR13A1 Protein, Human (Cell-Free, His) is 328 a.a., with molecular weight of 39.3 kDa.
OR5AL1 operates as an odorant receptor. OR5AL1 Protein, Human (Cell-Free, His) is the recombinant human-derived OR5AL1 protein, expressed by E. coli Cell-free, with N-10*His labeled tag. The total length of OR5AL1 Protein, Human (Cell-Free, His) is 328 a.a., with molecular weight of 39.6 kDa.
OR5V1 serves as an odorant receptor. OR5V1 Protein, Human (Cell-Free, His) is the recombinant human-derived OR5V1 protein, expressed by E. coli Cell-free, with N-10*His labeled tag. The total length of OR5V1 Protein, Human (Cell-Free, His) is 321 a.a., with molecular weight of 42.1 kDa.
The Serpin B6b Protein, an integral serpin family member, plays a crucial role as a serine protease inhibitor, regulating proteolytic activities. Its study enhances understanding of cellular processes related to proteolysis, with therapeutic applications. The classification within the serpin family emphasizes unique mechanisms and substrate specificity, providing insights into broader impacts on cellular processes. Further exploration of Serpin B6b's role promises to enhance knowledge of its contributions to both normal physiology and pathological conditions. Serpin B6b Protein, Mouse (sf9, His) is the recombinant mouse-derived Serpin B6b protein, expressed by Sf9 insect cells, with C-His labeled tag. The total length of Serpin B6b Protein, Mouse (sf9, His) is 377 a.a., with molecular weight of ~43 kDa.
The OGG1 protein is a DNA repair enzyme specifically designed to cleave DNA at the 8-oxoG residue and plays a key role in maintaining genome integrity. It demonstrates the ability to excise damaged bases such as 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine from the DNA structure (FAPY). OGG1 Protein, Human (GST) is the recombinant human-derived OGG1 protein, expressed by E. coli , with tag free. The total length of OGG1 Protein, Human (GST) is 345 a.a., with molecular weight of ~38.0 kDa.
KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free. The total length of KMT2D Protein, Human is 155 a.a., .
KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag. The total length of KMT2D Protein, Human (GST) is 155 a.a., .
IMPA1 protein provides essential inositol for the synthesis of phosphatidylinositol and polyphosphate inositol. IMPA1 Protein, Human (His) is the recombinant human-derived IMPA1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of IMPA1 Protein, Human (His) is 277 a.a., with molecular weight of ~30.0 kDa.
IMPA2, or Inositol monophosphatase 2, demonstrates enzymatic activity by utilizing various substrates such as myo-inositol monophosphates, scylloinositol 1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-AMP. Additionally, it has been implicated as the pharmacological target for the action of lithium ions (Li⁺) in the brain. IMPA2 Protein, Human (His) is the recombinant human-derived IMPA2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of IMPA2 Protein, Human (His) is 288 a.a., with molecular weight of ~30.0 kDa.
The Serpin B3 protein exhibits versatility in cellular regulation and may act as a papain-like cysteine protease inhibitor to modulate immune responses against tumor cells. Its dual role extends to inhibiting UV-induced apoptosis by inhibiting c-Jun NH(2)-terminal kinase (JNK1) activity, suggesting that Serpin B3 is involved in the stress response. Serpin B3 Protein, Human (HEK293, His) is the recombinant human-derived Serpin B3 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Serpin B3 Protein, Human (HEK293, His) is 390 a.a., with molecular weight of 41-50 kDa.